tirzepatide loss of exclusivity The peptide regulatory landscape in 2026 is in active flux. After the FDA placed 19 popular peptides in Category 2 in late 2023, HHS Secretary RFK Jr. announced in February 2026 that Top drug patent expirations in

They can evaluate whether dose escalation is appropriate, review your dietary patterns for hidden caloric sources, order blood work to check for metabolic issues, and discuss alternative formulations or combination approaches

Lifestyle information: Diet, exercise routines, and other habits that may affect treatment

Most people begin noticing weight changes between 4 and 12 weeks of consistent use

Having that open line of communication helped me adjust my plan and keep moving forward

[19] [20] Newer agents such as tirzepatide (a dual GLP-1/GIP receptor agonist) may become available in the UK for weight management subject to MHRA authorisation and NICE appraisal